Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2018

Open Access 01-12-2018 | Research

Malignant adnexal tumors of the skin: a single institution experience

Authors: Tolutope Oyasiji, Wei Tan, John Kane III, Joseph Skitzki, Valerie Francescutti, Kilian Salerno, Nikhil I. Khushalani

Published in: World Journal of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

Malignant adnexal tumors of the skin (MATS) are rare. We aimed to measure the survival of patients with MATS and identify predictors of improved survival.

Methods

A retrospective review of MATS treated at our institution from 1990 to 2012.

Results

There were 50 patients within the time period. Median age was 59.5 years (range 22–95); primary site was the head and neck (52%); most common histologic subtypes were skin appendage carcinoma (20%) and eccrine adenocarcinoma (20%); and the vast majority were T1 (44%). Most patients (98%) underwent surgical treatment. Chemotherapy and radiation were administered to 8 and 14% of patients, respectively. Recurrence rate was 12%. Median OS was 158 months (95% CI, 52–255). OS and recurrence-free survival at 5 years were 62.4 and 47.4% and at 10 years 56.7 and 41.5%, respectively. Five-year and 10-year disease-specific survival (DSS) was 62.9%. Age > 60 years was an unfavorable predictor of OS (HR 12.9, P < .0008) and recurrence-free survival (RFS) (HR 12.53, P < .0003). Nodal metastasis was a negative predictor of RFS (HR 2.37, P < 0.04) and DSS (HR 7.2, P < 0.03) while treatment with chemotherapy was predictive of poor DSS (HR 14.21, P < 0.03).

Conclusions

Younger patients had better OS and RFS. Absence of nodal metastasis translated to better RFS and DSS. Lymph node basin staging is worth considering in the workup and treatment.
Literature
1.
Martinez SR, Barr KL, Canter RJ. Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. Arch Dermatol. 2011;147(9):1058–62.CrossRefPubMed
2.
Waqas O, Faisal M, Haider I, Amjad A, Jamshed A, Hussain R. Retrospective study of rare cutaneous malignant adnexal tumors of the head and neck in a tertiary care cancer hospital: a case series. J Med Case Rep. 2017;11:67.CrossRefPubMedPubMedCentral
3.
Leboit P, Burg G, Weedon D, Sarasin A. World health organization classification of tumors: pathology & genetics: skin tumors, vol. 2006. Lyon: IARCPress; 2006.
4.
Blake PW, Bradford PT, Devesa SS, Toro JR. Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. Arch Dermatol. 2010;146(6):625–32.CrossRefPubMed
5.
Avraham JB, Villines D, Maker VK, August C, Maker AV. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes. J Surg Oncol. 2013;108(1):57–62.CrossRefPubMed
6.
Chiller K, Passaro D, Scheuller M, Singer M, McCalmont T, Grekin RC. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000;136(11):1355–9.PubMed
7.
Barnes J, Garcia C. Primary cutaneous adenoid cystic carcinoma: a case report and review of the literature. Cutis. 2008;81(3):243–6.PubMed
8.
Roozeboom MH, Lohman BG, Westers-Attema A, Nelemans PJ, Botterweck AA, van Marion AM, et al. Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. Acta Derm Venereol. 2013;93(4):417–21.CrossRefPubMed
9.
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003;21(1):43–52.CrossRefPubMed
10.
Guerriero S, Ruffolo C, Lombardi AR, Tirone A, Tirone G. Recurrent pleural effusion and pulmonary metastases from a cutaneous apocrine tumour of the axilla. Acta Chir Belg. 2007;107(6):697–9.CrossRefPubMed
11.
Gabillot-Carre M, Weill F, Mamelle G, Kolb F, Boitier F, Petrow P, et al. Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology. 2006;212(3):221–8.CrossRefPubMed
12.
Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158–65.CrossRefPubMed
13.
Barnes M, Hestley A, Murray DR, Carlson GW, Parker D, Delman KA. The risk of lymph node involvement in malignant cutaneous adnexal tumors. Am Surg. 2014;80(3):270–4.PubMed
14.
Ogata D, Kiyohara Y, Yoshikawa S, Kasami M. Treatment strategy for cutaneous apocrine carcinoma. Int J Clin Oncol. 2014;19(4):712–5.
15.
Romeu M, Foletti JM, Chossegros C, Dales JP, Berbis P, Cribier B, Guyot L. Malignant cutaneous adnexal neoplasms of the face and scalp: diagnostic and therapeutic update. J Stomatol Oral Maxillofac Surg. 2017;118(2):95–102.CrossRefPubMed
16.
Battistella M, Mateus C, Lassau N, Chami L, Boukoucha M, Duvillard P, et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol. 2010;24(2):199–203.CrossRefPubMed
17.
Piedbois P, Breau JL, Morere JF, Israel L. Sweat gland carcinoma with bone and visceral metastases. Prolonged complete remission lasting 16 months as a result of chemotherapy. Cancer. 1987;60(2):170–2.CrossRefPubMed
18.
De Iuliis F, Amoroso L, Taglieri L, Vendittozzi S, Blasi L, Salerno G, Lanza R, Scarpa S. Chemotherapy of rare skin adnexal tumors: a review of literature. Anticancer Res. 2014;34(10):5263–8.PubMed
Metadata
Title
Malignant adnexal tumors of the skin: a single institution experience
Authors
Tolutope Oyasiji
Wei Tan
John Kane III
Joseph Skitzki
Valerie Francescutti
Kilian Salerno
Nikhil I. Khushalani
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1401-y

Other articles of this Issue 1/2018

World Journal of Surgical Oncology 1/2018 Go to the issue

Research

Evaluation on prognostic efficacy of lymph nodes ratio (LNR) and log odds of positive lymph nodes (LODDS) in complicated colon cancer: the first study in emergency surgery

Case Report

Unusual presentation of a hepatocellular carcinoma as a potential late side effect of radiotherapy in a patient treated for Wilms tumor in childhood

Research

Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study

Research

Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity

Case Report

Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center

Research

Plasma levels of the proangiogenic protein CXCL16 remains elevated for 1 month after minimally invasive colorectal cancer resection